Patrick Van Beneden - Partner in Gimv's Health & Care team

Company profile

The Foundry Innovation and Research 1, Ltd. (FIRE1), was founded in 2013 and is the first European spinout of The Foundry, a highly successful medical device incubator from Menlo Park, California. The company, located in Ireland, focuses on developing a novel remote monitoring device to improve outcomes for patients suffering from an increased risk of heart failure. Early detection enables a timely intervention and adjustment of pharmacotherapy, thus avoiding hospitalisation, improving quality of life and lowering health care costs.

Investment rationale

FIRE1 is active in a market with growing unmet needs, as cardiac disease is currently the world’s leading cause of death. 

Growth strategy

The current financing will be used to complete a first-in-human study as well as for the submission of an IDE.

FIRE1

Patrick Van Beneden, Partner

Patrick Van Beneden joined Gimv in 1985 and has built a successful track record in life sciences, both in early and late stage investments and exits (Devgen, CropDesign, Plexxikon, Endosense,…).

He is currently representing Gimv on the boards of JenaValve, Complix, AgroSavfe, G-Therapeutics and FlandersBio and holds an observer seat at EndoStim. Former board seats include Innogenetics, Crucell, Hypnion (acquired by Eli Lilly), CropDesign (acquired by BASF), Astex and Ablynx.

Patrick has a degree in financial sciences from Vlekho in Brussels.

Contact

+32 3 290 21 36

Karel Oomsstraat 37
2018 Antwerpen

Belgium

Patrick Van Beneden